Results 1 to 10 of about 342 (145)

Clinically Meaningful Improvements in Cutaneous Lesions and Quality of Life Measures in Patients With Atopic Dermatitis With Greater Pruritus Reductions After Treatment With 60 mg Nemolizumab Subcutaneously Every 4 Weeks: Subgroup Analysis From a Phase 3, Randomized, Controlled Trial [PDF]

Journal of Dermatological Treatment, 2023
Background Data from the Japanese phase 3 Nemolizumab-JP01 study (JapicCTI-173740) found that nemolizumab in combination with topical treatments reduced pruritus associated with atopic dermatitis inadequately controlled with current therapies.
Kenji Kabashima, Makoto Kawashima, Takayo Matsumura   +2 more
exaly   +3 more sources

Nemolizumab for the Treatment of Atopic Dermatitis

Journal of Dermatological Treatment
Purpose Atopic dermatitis (AD) is a common, heterogeneous inflammatory skin disease characterized by chronic or relapsing eczematous lesions and intense pruritus, leading to reduced quality of life and increased mental health burden.
Raj J Chovatiya
exaly   +5 more sources

Clinical Factors Predicting Nemolizumab Response in Atopic Dermatitis

Journal of Allergy and Clinical Immunology: Global
Clinical predictors of response to nemolizumab, an anti-IL-31 receptor A antibody, were evaluated in patients with atopic dermatitis (AD). In a retrospective study of 14 Japanese patients, longer disease duration was significantly associated with poor ...
Kenji Kabashima, Saeko Nakajima, Satoru Yonekura   +2 more
exaly   +5 more sources

Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis

Pharmaceutics, 2023
Atopic dermatitis (AD), a pruritic, inflammatory chronic disease with multifactorial pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not only the immunologic dysfunction and microbiome dysbiosis but also the recovery
Raquel Leao Orfali, Valeria Aoki
doaj   +2 more sources

Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial

Dermatology and Therapy, 2023
Introduction Atopic dermatitis (AD), with its signs and symptoms of pruritus, dryness, and erythema, severely reduces the quality of life (QOL) of affected patients.
Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki, Makoto Kawashima, The Nemolizumab-JP01 Study Group   +4 more
doaj   +1 more source

A Case of Concurrent Exacerbation of Manifestations and Asthma After the Initiation of Nemolizumab Treatment for Atopic Dermatitis

JAAD Case Reports
Yoshimasa Nobeyama, Yozo Ishiuji
exaly   +3 more sources

Nemolizumab: un innovador tratamiento biológico para el control de la interleuquina 31 (IL-31) clave en la dermatitis atópica y el prurigo nodular

Actas Dermo-Sifiliográficas, 2022
Resumen: La citoquina IL-31 es una neurocitoquina que estimula las neuronas sensoriales relacionadas con el picor, contribuye a la inflamación, la disfunción y remodelación de la barrera epidérmica. Al interrelacionar los sistemas inmunológico y nervioso
E. Serra-Baldrich, L.F. Santamaría-Babí, J. Francisco Silvestre   +2 more
doaj   +1 more source

[Translated article] Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis

Actas Dermo-Sifiliográficas, 2022
Interleukin 31 (IL-31) is a neurocytokine that stimulates sensory neurons involved in pruritus. It contributes to skin barrier inflammation, dysfunction, and remodeling.
E. Serra-Baldrich, L.F. Santamaria-Babí, J. Francisco Silvestre   +2 more
doaj   +1 more source

Safety and Efficacy of Nemolizumab for Patients with Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trial

Frontiers in Immunology, 2022
BackgroundNemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.ObjectiveThis study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of ...
Junqin Liang, Fengxia Hu, Maoli Dan, Yingbing Sang, Kailibinuer Abulikemu, Qian Wang, Yongzhen Hong, Xiaojing Kang   +7 more
doaj   +1 more source

Efficacy and safety of nemolizumab in prurigo nodularis: a systematic review and meta-analysis of randomized controlled trials [PDF]

Anais Brasileiros de Dermatologia
Background Prurigo nodularis (PN) is a chronic, debilitating inflammatory skin disorder characterized by persistent itching, firm pruritic nodular lesions, and evidence of frequent scratching, like excoriation, and lichenification.
Ana Carolina Putini Vieira, Maria Antônia Costa Cruz Akabane, Gianna Carolinne Graff Caletti, Kélen Klein Heffel, Amanda Tauana Oliveira e Silva   +4 more
doaj   +1 more source